Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK says it disagrees with California state court ruling on Zantac
06:13am, Friday, 24'th Mar 2023
U.K. pharmaceutical giant GSK on Friday said it disagreed with a California state court ruling on Zantac, or ranitidine, and its links with cancer. “Following the 13 epidemiological studies conducte
Top 40 High-Yield Blue-Chip U.K. Stocks: Spring 2023
10:16pm, Wednesday, 22'nd Mar 2023
Much has changed since the last update in September, with banks now hogging many of the top spots. Bank shares have gone down in the last couple of weeks and their dividend yields have gone up, becaus
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?
08:45am, Friday, 17'th Mar 2023
The vaccine's revenue would help Pfizer make up for looming patent cliffs. GSK's annual financials were the healthiest of the three companies.
GSK rises as Deutsche upgrades to buy with 1,700p target
04:42am, Friday, 17'th Mar 2023
GSK PLC (LSE:GSK, NYSE:GSK)'s shares jumped 1.8% in early exchanges in London supported by an upgrade by Deutsche Bank. The German investment bank has put the FTSE 100-listed pharma giant on its ‘bu
Johnson & Johnson: Creating Shareholder Value
03:42pm, Tuesday, 14'th Mar 2023
Johnson & Johnson ( JNJ , Financial), one of the world's largest health care companies, has been making waves in the industry with its diverse pharmaceutical pipeline, a mix of opportunities and chall
GSK scores phase III success with meningococcal disease vaccine
03:43am, Tuesday, 14'th Mar 2023
GSK PLC (LSE:GSK, NYSE:GSK) has announced positive results from its phase III trial of its MenABCWY combination vaccine candidate in meningococcal, a major cause of meningitis and septicaemia. The dru
3 High Dividend Stocks With Attractive Total Return Potential
03:11pm, Friday, 10'th Mar 2023
In the current economic climate of rising interest rates, persistent inflation, simmering geopolitical risks and looming recessionary threats, it's crucial to prioritize quality, safety and high divid
Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock?
08:30am, Sunday, 05'th Mar 2023
GSK's RSV vaccine candidate could prevent deaths and hospitalizations in older patients. The product could end up generating over $1 billion in annual revenue for the company.
March 2023 Stock Considerations
03:46am, Saturday, 04'th Mar 2023
2023 is flying by as two months are already in the books and that fact simply highlights to me the importance of staying invested in the stock market during the good times and bad. VZ stock is trading
GSK neck and neck with Pfizer in the race to get first RSV jab to market
05:19am, Thursday, 02'nd Mar 2023
GSK PLC (LSE:GSK, NYSE:GSK)'s respiratory syncytial virus (RSV) vaccine has been endorsed by advisors to the US Food & Drug Administration, who assessed its safety and efficacy in older adults. The d
FDA advisory panel votes in favor of adult RSV vaccine from GSK PLC
03:18pm, Wednesday, 01'st Mar 2023
CNBC's Meg Tirrell joins 'Power Lunch' to discuss GSK PLC's RSV vaccine receiving FDA support, ongoing questions around the drug's approval and the timeline for the drug to be available for children.
FDA advisors recommend GSK's RSV vaccine for older adults, but flag potential safety risks
02:33pm, Wednesday, 01'st Mar 2023
The Food and Drug Administration's independent panel of advisors on Wednesday recommended GlaxoSmithKline's RSV vaccine for adults ages 60 and older, though they flagged potential safety issues over n
FDA says Guillain-Barre syndrome is possible risk of Pfizer's RSV vaccine for older adults
02:15pm, Friday, 24'th Feb 2023
The FDA sees a potential risk and has asked Pfizer to conduct a safety study on Guillain-Barre after a potential approval, which the company said it would do.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:32am, Friday, 17'th Feb 2023
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Competition Coming For AbbVie's Blockbuster Humira
01:08am, Thursday, 16'th Feb 2023
It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
